Ken Griffin Immunity Bio, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 443,400 shares of IBRX stock, worth $2.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
443,400
Previous 95,400
364.78%
Holding current value
$2.8 Million
Previous $478,000
398.12%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding IBRX
# of Institutions
191Shares Held
66.7MCall Options Held
2.27MPut Options Held
3.23M-
State Street Corp Boston, MA14.2MShares$89.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.5MShares$85.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.4MShares$65.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.48MShares$22 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.55MShares$9.79 Million0.01% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $2.53B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...